The global head and neck cancer drugs market offers treatment options for cancers that begin in the oral cavity, pharynx, larynx, paranasal sinuses, and nasal cavity. Head and neck cancers can be treated using chemotherapy, radiation therapy, targeted drug therapy, or a combination of these treatments. Targeted drug therapy options include cetuximab, nimotuzumab, and panitumumab which help block the effects of epidermal growth factor receptors (EGFR) that fuel cancer cell growth. The global head and neck cancer drugs market is estimated to be valued at US$ 1986.3 Mn or Mn in 2023 and is expected to exhibit a CAGR of 8.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

One of the key drivers for the growth of the head and neck cancer drugs market size is the rising incidence of head and neck cancer globally. According to the Global Cancer Observatory, there were over 905,723 new cases of head and neck cancers in 2020 worldwide. The incidence is higher in lower-middle income countries due to risk factors like consumption of tobacco and alcohol. Development of newer targeted therapies for treatment is also fueling the market growth. For instance, in May 2020, Merck received FDA approval for Keytruda (pembrolizumab), a PD-1 inhibitor, for use in combination with platinum-based chemotherapy and fluorouracil for recurrent or metastatic head and neck squamous cell carcinoma.

SWOT Analysis
Strength: Head and neck cancer drugs have seen major advancements in recent years. Three new drugs were approved between 2019-2022, offering more targeted and effective treatment options with fewer side effects. The development of combination therapies and immunotherapies have improved survival rates.

Weakness: Treatment of head and neck cancers is a complex process requiring a multidisciplinary approach. Surgery or radiation are usually the primary treatments and drug therapies play a supplementary role. High development costs and long approval timelines make these drugs expensive for patients.

Opportunity: Only a few molecularly targeted drugs are currently approved for head and neck cancers. Large unmet needs remain for recurrent/metastatic cases. More research into genetic biomarkers can lead to identification of new drug targets and precision therapies. Growing elderly population is increasing the incidence of these cancers.

Threats: Competing areas within oncology receive higher research funding. Alternative treatment methods like gene or stem cell therapies may displace drug therapies in the future. Environmental factors that cause these cancers like smoking continue to pose challenges.

Key Takeaways

The global head and neck cancer drugs market is expected to witness high growth over the forecast period supported by new product launches and approvals. The market size is projected to reach US$ 1986.3 Mn by 2023.

Regional analysis: North America currently dominates the market due to large patient volumes, advanced healthcare infrastructure and favorable reimbursement. The Asia Pacific region is expected to witness the fastest growth led by China and India. Growing awareness, increasing healthcare spending, and rising incidences of head and neck cancers are driving the regional market.

Key players analysis: Key players operating in the head and neck cancer drugs market are Johnson & Johnson Services, Inc., Double Medical Technology Inc., Orthofix Holdings, Inc., Ortho-SUV Ltd., Response Ortho LLC, Smith & Nephew, Stryker Corporation , Zimmer Biomet, Auxein Medical, Acumed, Tasarimmed T?bbi Mamuller San. Tic A.?, Orthopaedic Implant Company, Gexfix SA, WishBone Medical, Inc., and Matrix Meditech. These companies are focusing on new product launches, collaborations and acquisitions to strengthen their market positions.

Get more insights on this topic: https://www.trendingwebwire.com/head-and-neck-cancer-drugs-market-size-and-outlook/